Abemaciclib in real clinical practice of adjuvant therapy of HR+/HER2- high-risk breast cancer: experience of centers in Moscow. (2025). Voprosy Onkologii, 71(3), OF-2319. https://doi.org/10.37469/0507-3758-2025-71-3-OF-2319